Avidity Biosciences Inc RNA

NAS: RNA | ISIN: US05370A1088   31/05/2024
26,86 USD (-0,74%)
(-0,74%)   31/05/2024

29 mei 2024 · Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress · Persbericht

21 mei 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

15 mei 2024 · Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors · Persbericht

9 mei 2024 · Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights · Persbericht

8 mei 2024 · Avidity Biosciences to Participate in Upcoming Investor Conference · Persbericht

8 mei 2024 · Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 · Persbericht

22 april 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 maart 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 maart 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

4 maart 2024 · Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial · Persbericht

29 februari 2024 · Avidity Biosciences Honors Rare Disease Day® · Persbericht

29 februari 2024 · Avidity Biosciences Announces Oversubscribed $400 Million Private Placement · Persbericht

28 februari 2024 · Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights · Persbericht

27 februari 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 februari 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 februari 2024 · Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping · Persbericht

15 februari 2024 · Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

22 januari 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 januari 2024 · Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth · Persbericht

21 december 2023 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties